HHS Signals MAHA Inquiry on Baby Formula Is Next in Queue

Long overdue, thorough public inquiry is now inevitable.

From the moment the Human Foods Program was reorganized and the MAHA framework articulated its structural objectives, infant formula stood out as the inevitable next front. The regulatory lag was measurable. The contaminant discourse was already active. The nutrient standards were anchored in 1998-era science. The supply-chain fragility of 2022 remained fresh in institutional memory. Those closest to reform strategy knew that formula would move once upstream food chemical initiatives cleared the runway.

Now it has.

Operation Stork Speed, announced March 18, 2025, defined scope: strengthened safety testing, expanded contaminant screening, labeling modernization, international benchmarking, and NIH collaboration to close gaps in long-term formula-feeding outcomes.

On May 13, 2025, FDA formally initiated the statutory review of infant formula nutrient requirements—the first comprehensive review since 1998. That 27-year interval is scientifically untenable in a domain where lipid metabolism research, micronutrient bioavailability data, and developmental neurobiology have advanced continuously.

And recently, on February 10, 2026 Human Foods Program 2026 Priority Deliverables codified what was already evident: infant formula modernization is embedded inside MAHA implementation. Exposure data releases for lead, arsenic, cadmium, mercury, and PFAS are scheduled under Operation Stork Speed. Nutrient reevaluation is underway.

The FY2026 HHS Budget in Brief assigns $15 million toward modernization of formula oversight and surveillance. Budgets reveal priorities more clearly than speeches.

This progression was expected.

Infant formula is a unique regulatory category. Approximately three-quarters of U.S. infants receive formula within the first six months of life, and roughly 40% rely on it as their sole nutrition source during that period.

Unlike conventional foods, formula functions as complete nutrition during a phase of peak neurogenesis, synaptogenesis, and myelination. During the first year of life, brain volume doubles. The infant blood-brain barrier remains developmentally dynamic. Renal clearance capacity differs from adult physiology. Trace element exposures that are inconsequential in adults can accumulate differently in infants due to immature excretory mechanisms and higher intake per body weight.

The current regulatory baseline requires 30 specified nutrients with minimum concentrations and maximum limits for ten. Those parameters were designed using data that predate modern research on:

• Long-chain polyunsaturated fatty acids (LCPUFAs) and the ratio-dependent roles of DHA and arachidonic acid (ARA) in cortical development.
• The importance of structured triglycerides and positional palmitate (sn-2 palmitate) in fat and calcium absorption.
• Choline’s role in hippocampal development and epigenetic methylation pathways.
• Lutein and zeaxanthin in retinal and neural tissue deposition.
• The gut–brain axis and the influence of oligosaccharides, prebiotics, and microbial colonization patterns on immune programming.

None of these domains were fully integrated into 1998 standards.

The contaminant dimension is equally overdue.

Unacceptable heavy metals enter formula through multiple pathways: raw ingredient contamination, soil uptake in plant-derived components, processing equipment, packaging migration, and water inputs. Arsenic contamination in rice-derived ingredients reflects known soil persistence and groundwater mobilization. Cadmium accumulates in certain grains and cacao derivatives. Lead persists in environmental dust and can enter supply chains via agricultural or manufacturing pathways. Mercury, though less common in formula matrices than in fish products, can appear via environmental deposition. PFAS contamination can originate from packaging materials, industrial water sources, or environmental persistence.

Exposure assessment must consider:

• Concentration per kilogram of product.
• Reconstitution water quality.
• Average daily intake in grams per kilogram body weight.
• Bioavailability and speciation (for example, inorganic arsenic versus organic forms).
• Infant renal clearance rates and body-weight–normalized intake.

An infant consuming 150 mL/kg/day of formula experiences a dramatically different dose-per-body-weight profile than an adult consuming the same contaminant concentration.

The upcoming exposure dataset under Operation Stork Speed is expected to detail measured concentrations, detection limits, laboratory methods, and intake modeling assumptions. Without those elements, risk characterization cannot be evaluated scientifically.

Then there is aluminum.

Aluminum exposure in infants has been documented in peer-reviewed literature for more than a decade. Burrell and Exley (2010) reported aluminum concentrations in infant formulas and raised concerns regarding cumulative exposure. Chuchu et al. (2013) concluded that aluminum levels remained elevated across products tested. Redgrove et al. (2019) reported aluminum contamination in prescription infant formulas.

Aluminum is not classically grouped with lead, arsenic, cadmium, and mercury in federal contaminant narratives, yet it remains biologically relevant. Infants possess limited renal excretion capacity relative to adults. Aluminum can accumulate in bone and potentially in neural tissue under certain conditions. Aluminum is used in animal studies to induce autoimmunity conditions found in children and adults. Parenteral nutrition literature has long addressed aluminum exposure concerns in preterm infants. The question is not rhetorical; it is analytical: will aluminum appear in the federal dataset?

If excluded, the methodological rationale must be explicit.

Consumer Reports’ independent testing of 41 powdered formulas for arsenic, lead, PFAS, BPA, and acrylamide accelerated public pressure for federal transparency.

Independent testing, even when methodologically imperfect, shifts institutional risk calculations. Once data circulate, federal agencies must either validate, refute, or contextualize them with higher-resolution analysis.

Secretary Kennedy has stated publicly that contaminant study results will be released and include metals such as cadmium, mercury, and lead.

S.272, the Protect Infant Formula from Contamination Act, introduced January 28, 2025, tightens contamination detection and reporting obligations in direct response to the 2022 Cronobacter-linked shutdown that triggered the national formula shortage. The bill shifts the reporting trigger forward: manufacturers must notify FDA within one business day of confirming a positive test for specified pathogens such as Cronobacter sakazakii or Salmonella—even if the product has not left the facility. Notification must include confirmatory lab results and, where available, genomic sequencing data, along with lot information and corrective action plans. The FDA, in turn, must respond within one business day and, within ninety days, verify that appropriate root-cause investigation and corrective measures have been implemented. The design is procedural but consequential: it compresses latency, formalizes strain-level epidemiology in reporting, and builds reciprocal timelines into oversight.

Scientifically, the focus is warranted. Powdered formula is not sterile; microbial risk management depends on environmental control, rapid detection, and immediate containment—especially for infants under two months, who face elevated risk of sepsis or meningitis from Cronobacter. By moving the activation point from post-distribution recall to pre-distribution confirmation, S.272 lowers the threshold for federal engagement and reduces the probability that contaminated product enters commerce. It does not rewrite nutrient standards or set new heavy metal limits; it fixes time. In the broader modernization now underway—nutrient review, toxic element exposure releases, and oversight funding—S.272 provides the enforcement spine.

None of this emerged spontaneously. The MAHA Commission strategy explicitly lists raising infant formula standards among executive priorities. It reflects a convergence: decades of waiting for those in positions of power to act, increasing nutrient stagnation, contaminant scrutiny, growing undeniable evidence of a role of aluminum in neurodevelopmental disorders, supply resilience concerns, and a policy architecture designed to interrogate systemic food safety.

The scientific challenge is straightforward and demanding:

1. Define nutrient modernization using contemporary metabolic, neurodevelopmental, and immunologic data.

2. Quantify contaminant exposure with validated methods, transparent modeling, and reproducible data release.

3. Distinguish environmental baseline presence from actionable manufacturing contamination.

4. Address aluminum neurotoxicity as the scientific record demands.

5. Protect supply resilience while reforming standards.

6. Avoid risk inflation narratives that destabilize parental behavior without improving safety.

Formula modernization is not symbolic reform. It is a systems-level recalibration of the only regulated food category that can serve as complete nutrition during the most developmentally sensitive period of life.

From the outset of MAHA’s structural reorganization, this was visible. Infant formula combines the highest vulnerability population, the clearest regulatory lag, and the most concentrated scientific leverage point.

Let’s be grateful that HHS and others are finally tackling exposures in this all-important population.